Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Profit After Tax (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Profit After Tax for 6 consecutive years, with -$23.0 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 31.5% to -$23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$50.2 million through Dec 2025, up 17.21% year-over-year, with the annual reading at -$50.2 million for FY2025, 17.21% up from the prior year.
  • Profit After Tax hit -$23.0 million in Q4 2025 for Insight Molecular Diagnostics, down from -$10.9 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $6.0 million in Q1 2023 to a low of -$45.0 million in Q4 2022.
  • Historically, Profit After Tax has averaged -$12.9 million across 5 years, with a median of -$9.5 million in 2022.
  • Biggest YoY gain for Profit After Tax was 274.6% in 2023; the steepest drop was 510.92% in 2023.
  • Year by year, Profit After Tax stood at -$35.9 million in 2021, then fell by 25.34% to -$45.0 million in 2022, then skyrocketed by 64.44% to -$16.0 million in 2023, then plummeted by 109.55% to -$33.5 million in 2024, then soared by 31.5% to -$23.0 million in 2025.
  • Business Quant data shows Profit After Tax for IMDX at -$23.0 million in Q4 2025, -$10.9 million in Q3 2025, and -$9.7 million in Q2 2025.